يعرض 1 - 20 نتائج من 240 نتيجة بحث عن '(( ct ((((largest decrease) OR (marked decrease))) OR (larger decrease)) ) OR ( 140 a decrease ))', وقت الاستعلام: 0.61s تنقيح النتائج
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Table 1_IL-10/STAT5 axis suppresses miR-140 to upregulate B7-H4 expression in RAW264.7 cells.docx حسب Dandan Zhu (513418)

    منشور في 2025
    "…Results by Western blot and ChIP further indicated that IL-10 could downregulate miR-140 promoter activity in a STAT5 dependence manner. …"
  7. 7
  8. 8

    Supporting information_raw dataset. حسب Nusrat Jahan Mumu (22305359)

    منشور في 2025
    "…While HR enhanced most soil P fractions, higher N rates (>N100) tended to decrease labile-Pi (inorganic) fractions by up to 45% suggesting a potential decline in plant-available P. …"
  9. 9

    Soil phosphorus fractionations procedure [41]. حسب Nusrat Jahan Mumu (22305359)

    منشور في 2025
    "…While HR enhanced most soil P fractions, higher N rates (>N100) tended to decrease labile-Pi (inorganic) fractions by up to 45% suggesting a potential decline in plant-available P. …"
  10. 10
  11. 11

    Probability of Cost-Effectiveness Across CET. حسب Yiping An (20609789)

    منشور في 2025
    "…</p><p>Results</p><p>The current price of AOM in China is relatively high (US$418.140). To assess its cost-effectiveness in the context of potential price negotiations with China Healthcare Security Administration (CHS) for inclusion in the National Reimbursement Drug List (NRDL), we simulated a 40% price reduction (US$257.619). …"
  12. 12

    Base-case analysis. حسب Yiping An (20609789)

    منشور في 2025
    "…</p><p>Results</p><p>The current price of AOM in China is relatively high (US$418.140). To assess its cost-effectiveness in the context of potential price negotiations with China Healthcare Security Administration (CHS) for inclusion in the National Reimbursement Drug List (NRDL), we simulated a 40% price reduction (US$257.619). …"
  13. 13
  14. 14

    S1 Data - حسب Bowen Deng (3123237)

    منشور في 2024
    "…We identified 4 longitudinal trajectories of blood glucose, including class 1 (a low initial average blood glucose level with steady trend within 24 hours), class 2 (a high initial average blood glucose with gently decreased trend), class 3 (the highest initial average blood glucose with rapidly decreased trend) and class 4 (a high initial average blood glucose level with the trend that increased at first and then decreased). …"
  15. 15

    Characteristics of AMI patients with DM. حسب Bowen Deng (3123237)

    منشور في 2024
    "…We identified 4 longitudinal trajectories of blood glucose, including class 1 (a low initial average blood glucose level with steady trend within 24 hours), class 2 (a high initial average blood glucose with gently decreased trend), class 3 (the highest initial average blood glucose with rapidly decreased trend) and class 4 (a high initial average blood glucose level with the trend that increased at first and then decreased). …"
  16. 16
  17. 17
  18. 18

    Data Sheet 1_Empagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure.pdf حسب Hua Wei (60877)

    منشور في 2025
    "…Post-treatment, MRGlu and glucose uptake decreased markedly in the empagliflozin (EMPG) group, while no significant changes were observed in the fenofibrate (FF) group. …"
  19. 19
  20. 20

    The Complete Guide to EB-2 National Interest Waiver: Comprehensive Analysis of Matter of Dhanasar for International Professionals حسب Wederson Marinho (21029060)

    منشور في 2025
    "…</p><p dir="ltr">Key findings include: (1) dramatic decrease in approval rates from 96% (2022) to 43% (2024), requiring more rigorous preparation; (2) democratization of access through self-petition movement, saving USD 10,000-20,000 in legal fees; (3) realistic timeline of 3-5 years for most countries due to visa bulletin retrogression; (4) critical importance of quantitative impact evidence and expert letters in strengthening petitions; (5) clarification that I-140 filing remains paper-based as of November 2025.…"